Following publication, concerns were raised regarding the scientific validity of the article. An investigation was therefore conducted in accordance with our established procedures. As the raw data presented in the manuscript could not be provided, the Specialty Chief Editor concluded that the conclusions and assertions could not be sufficiently supported by the material provided.
The retraction of the article was approved by the Chief Editors of Pharmacology and the Editor-in-Chief of Frontiers.
The authors agree to the retraction.
Summary
Keywords
Osteosarcoma, MG63 cells, DDX5, TCF12, cyclin E1
Citation
Frontiers Editorial Office (2019) Retraction: DEAD-Box Helicase 5 Interacts With Transcription Factor 12 and Promotes the Progression of Osteosarcoma by Stimulating Cell Cycle Progression. Front. Pharmacol. 10:1657. doi: 10.3389/fphar.2019.01657
Received
17 December 2019
Accepted
17 December 2019
Published
23 December 2019
Approved by
Salvatore Salomone, University of Catania, Italy
Volume
10 - 2019
Updates
Copyright
© 2019 Frontiers Editorial Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Editorial Office, editorial.office@frontiersin.org
This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.